Maynard Um
-
-
-
-
-
-
-
4D Molecular Therapeutics, Inc. (FDMT) Misses Q1 EPS by 1c
-
-
-
-
-
-
-
4D Molecular Therapeutics, Inc. (FDMT) Reports In-Line Q3 EPS
-
-
-
-
-
-
-
4D Molecular Therapeutics (FDMT) Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution
-
-
-
-
-
-
-
4D Molecular Therapeutics (FDMT) Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway
-
-
-
-
-
-
-
BMO Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT)
-
-
-
-
-
-
-
RBC Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT)
-
454,329 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

